ストックスクリーナーアプリを入手
5.00
3.52%
0.17
アフターアワーズ：
5.00
前日終値:
$4.83
開ける：
$4.84
24時間の取引高:
13,143
Relative Volume:
0.87
時価総額：
$44.46M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-5.12%
1か月 パフォーマンス:
-37.03%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$4.84
$5.18
1週間の範囲:
$4.557
$5.79
52週間の値動き範囲:
$3.81
$10.28
Serina Therapeutics Inc Stock (SER) Company Profile
SER を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| SER | 5.00 | 44.46M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Serina Therapeutics Inc (SER) 最新ニュース
Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewswire
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan - The Manila Times
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan - GlobeNewswire Inc.
TSX Composite Capped Index (TOOC) QuotePress Release - The Globe and Mail
AgeX Therapeutics stock hits 52-week low at $5.72 - Investing.com India
AgeX Therapeutics stock hits 52-week low at $5.72 By Investing.com - Investing.com Canada
Serina Therapeutics CDO Presents at Injectables Summit - TipRanks
Serina Therapeutics to Present at the 14th Annual Injectables Summit - GlobeNewswire
SLM initiated with a Buy at BofA - TipRanks
Serina Therapeutics director buys $6.9k in company stock By Investing.com - Investing.com Australia
Serina Therapeutics director buys $6.9k in company stock - Investing.com India
Biotech Soars On Material Transfer Agreement - Invezz
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Seelos Therapeutics Inc Inc. (SEEL) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Savaria (TSE:SIS) Trading Down 4.1% - MarketBeat
SThree Q3 net fees slip 8% amid challenging conditions - Staffing Industry Analysts
UK recruiter SThree falls on lower Q3 net fee - XM
SThree plc Navigates Market Headwinds in Q3 - TipRanks
Serabi Gold (LON:SRB) Reaches New 12-Month High at $91.97 - MarketBeat
Quarterly Metrics: Quick and Current Ratios for SELLAS Life Sciences Group Inc (SLS) - The Dwinnex
Ready to Jump After Recent Trade: SELLAS Life Sciences Group Inc (SLS) - SETE News
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval - Benzinga
Director Gregory Bailey Acquires 14,388 Shares of Serina Therapeutics Inc (SER) - Stockxpo
Serina Therapeutics director buys $88.2k in company stock By Investing.com - Investing.com South Africa
Serina Therapeutics director buys $88.2k in company stock - Investing.com
Sanofi (NASDAQ: SNY) Secures FDA Approval for Multiple Myeloma Drug in Newly Diagnosed Patients - ABBO News
Serina Therapeutics appoints new CEO with strategic goals By Investing.com - Investing.com Australia
Serina Therapeutics appoints new CEO with strategic goals - Investing.com
Serina Therapeutics Names Steven Ledger as Permanent CEO - TipRanks
Serina Therapeutics Interim CEO Attends Global Investment Conference - TipRanks
Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Serina Therapeutics director buys $14.7k in company stock - Investing.com
Serina Therapeutics director buys $140k in company stock - Investing.com India
Director Gregory Bailey Acquires 19,200 Shares of Serina Therapeutics Inc (SER) - Yahoo Finance
Serina Therapeutics director buys $45k in company stock - Investing.com
Serina Therapeutics Welcomes Gregory Curhan as New CFO - TipRanks
Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewswire
Nima Farzan named CEO of Latigo - BioCentury
Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation - GlobeNewswire
Injectable Drug Delivery Market Size to Hit USD 1,630.73 Bn by 2033 - BioSpace
Enable Injections makes C-suite move following slew of new partnershipsCincinnati Business Courier - Cincinnati Business Courier
Enable Injections & Serina Partner to Develop Novel Parkinson’s Treatment - HIT Consultant
Enable Injections and Serina Therapeutics Announce - GlobeNewswire
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights - Yahoo Finance
Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman - GlobeNewswire
Why VirTra Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving PremarketVirTra (NASDAQ:VTSI) - Benzinga
Serina completes AgeX merger, targets neurological diseases and pain - Longevity.Technology
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics - GlobeNewswire
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results - Yahoo Finance
AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc.AGE - Business Wire
AgeX Therapeutics Postpones Merger Completion with Serina - TipRanks
Serina Therapeutics Inc (SER) 財務データ
Serina Therapeutics Inc (SER) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):